High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

Hon Y. Chan; Frederick J Meyers; Jerry P. Lewis

doi:10.1007/BF00570500

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

Hon Y. Chan, Frederick J Meyers, Jerry P. Lewis

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

Original language	English (US)
Pages (from-to)	265-266
Number of pages	2
Journal	Cancer Chemotherapy and Pharmacology
Volume	20
Issue number	3
DOIs	https://doi.org/10.1007/BF00570500
State	Published - Sep 1987

ASJC Scopus subject areas

Pharmacology
Oncology
Cancer Research

Access to Document

10.1007/BF00570500

Fingerprint Dive into the research topics of 'High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia'. Together they form a unique fingerprint.

Cite this

@article{e9d7236afc6b4ea39d3f925af98eb843,

title = "High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia",

abstract = "In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.",

author = "Chan, {Hon Y.} and Meyers, {Frederick J} and Lewis, {Jerry P.}",

year = "1987",

month = sep,

doi = "10.1007/BF00570500",

language = "English (US)",

volume = "20",

pages = "265--266",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "3",

}

TY - JOUR

T1 - High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

AU - Chan, Hon Y.

AU - Meyers, Frederick J

AU - Lewis, Jerry P.

PY - 1987/9

Y1 - 1987/9

N2 - In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

AB - In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

UR - http://www.scopus.com/inward/record.url?scp=0023627491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023627491&partnerID=8YFLogxK

U2 - 10.1007/BF00570500

DO - 10.1007/BF00570500

M3 - Article

C2 - 3677301

AN - SCOPUS:0023627491

VL - 20

SP - 265

EP - 266

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -